Skip to main content

Table 1 Patient characteristics

From: Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study

  RA patients
(n = 100)
Controls
(n = 200)
p
Age at index date, years, mean (SD) 62.1 (12.9) 62.4 (13.9) 0.87
Female, n (%, 95 CI) 78 (78, 68.7–85.1) 156 (78, 71.7–83.2) 1
Follow up, years, median (IQR) 9.5 (5.9–13.4) 7.4 (IQR 2.4–12.3) < 0.001
Seropositive Rheumatoid Factor and/or ACPA, n (%, 95 CI) 97,7 (97,7, 92.0–99.5)   
Use DMARDs, n (%, 95 CI) 94 (94, 87.1–97.3)   
Use biologic DMARDs, n (%, 95 CI) 20 (20, 13.2–29.1)   
BMI < 20, n (%, 95 CI) 5 (5.3, 2.2–12.1) 1 (0.6, 0.1–4.3) 0.02
Ever Smoker, n (%, 95 CI) 33 (33, 24.4–42.9) 31 (15.6, 11.1–21.3) 0.001
Menopause age, years, median (IQR) 47.8 (40.7–51) 48.4 (44.6–51.4) 0.27
Age at first Bone Mineral Densitometry, years, median (IQR) 62.7 (54.4–74.8) 67.0 (58.9–75.5) 0.09
Osteopenia at first densitometry, n (%, 95 CI) 21 (28.4, 19.2–39.8) 31 (35.6, 26.2–46.3) 0.33
Osteoporosis at first densitometry, n (%, 95 CI) 23 (31.3, 21.5–42.6) 22 (25, 16.9–35.2) 0.39
Osteoporosis at any densitometry, n (%, 95 CI) 27 (36.5, 26.2–48.1) 24 (27.3, 18.9–37.6) 0.21
Anti-resorptives use ever, n (% 95 CI) 24 (24.0%, 16.6–33.4) 30 (15.0%, 10.7–20.7) 0.06
Corticosteroid use ever, n (%, 95 CI) 69 (69.0, 59.2–77.3) 5 (2.5, 1.0–5.9) < 0.001
Prednisone use > = 20 mg/day ever, n (%, 95 CI) 5 (5.0, 2.1–11.5) 1 (0.5, 0.1–3.5) 0.01
Corticosteroid use > = 3 months, n (%, 95 CI) 63 (63.0, 53.1–71.9) 4 (2.0, 0.7–5.2) < 0.001